Advertisement

Topics

Novartis receives EU approval for breast cancer drug Kisqali

02:44 EDT 24 Aug 2017 | Reuters

ZURICH (Reuters) - Novartis AG said its drug Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer, bolstering the Swiss drugmaker's bid to challenge U.S. rival Pfizer's Ibrance.

Original Article: Novartis receives EU approval for breast cancer drug Kisqali

NEXT ARTICLE

More From BioPortfolio on "Novartis receives EU approval for breast cancer drug Kisqali"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...